Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Completed × Rogaratinib × Clear all

Phase

Phase 1 5 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 1

Interventions

Fluorouracil 21 Cisplatin 20 Oxaliplatin 15 Gemcitabine 15 Radiotherapy 14 Docetaxel 14 Paclitaxel 13 Capecitabine 13 Carboplatin 12 Bevacizumab 12 Leucovorin 11 Cyclophosphamide 11 Irinotecan 10 Drug Therapy 10 Cytarabine 9 Magnetic Resonance Spectroscopy 7 Dexamethasone 7 Saline Solution 6 Rituximab 6 Nivolumab 6 Methotrexate 6 Letrozole 6 Exercise 6 Etoposide 6 Electroporation 6 pembrolizumab 5 Melphalan 5 Lidocaine 5 Filgrastim 5 Doxorubicin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03410693 2022-09-28

FORT-1

Bayer

Phase 2/3 Completed

175 enrolled 19 charts

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡